news
Grail's Galleri cancer test fails primary endpoint in UK trial
Grail's multicancer detection blood test, Galleri, didn't hit its primary goal in a 140,000-person UK trial, failing to reduce late-stage cancer diagnoses. This was a big moment at the ASCO scientific meeting, especially for a test that promised early detection for multiple cancer types. The results mean we're still waiting for that one-and-done cancer screen.
Grail's multicancer detection blood test, Galleri, didn't hit its primary goal in a 140,000-person UK trial, failing to reduce late-stage cancer diagnoses. This was a big moment at the ASCO scientific meeting, especially for a test that promised early detection for multiple cancer types. The results mean we're still waiting for that one-and-done cancer screen.
The architecture take
So, the Galleri test didn't quite deliver, and for anyone watching the early detection space, that's a cold splash of reality. I thought we were getting closer to a simple blood test that would catch cancers before they really took hold, but this trial says not yet. The mechanism here is about circulating tumor DNA – basically, fragments of cancer cells floating in your blood. The idea is to find these fragments early. But the trial didn't show a reduction in late-stage cancers, which was the big 'so what' for patients. It's a reminder that biology is messy, and finding something and finding something meaningful for health outcomes are two very different things. For now, it means we stick to the less glamorous, but proven, screenings like mammograms and colonoscopies. Don't go chasing unicorn tests when solid, if inconvenient, options exist.